Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 known ✓ | O43526 | 6/20 | 0.54 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.35 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.35 |
| ▸ | CYP19A1 known ✓ | P11511 | 2/20 | 0.33 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9377639 | 0.98 | KCNQ2 (0.55) | KCNQ2CYP3A4CYP1A2CYP2C9ALOX15 | |
| SCHEMBL9267623 | 0.85 | CYP3A4 (0.57) | KCNQ2CYP3A4CYP1A2CYP2C9ALOX15 | |
| SCHEMBL9261670 | 0.84 | KCNQ2 (0.47) | KCNQ2CYP3A4CYP1A2CYP2C9ALOX15 | |
| SCHEMBL9282773 | 0.77 | TXNRD1 (0.38) | ALOX15ALDH1A1ADRA1DADRA1AADRA1B | |
| SCHEMBL9387496 | 0.74 | ALDH1A1 (0.61) | KCNQ2CYP3A4CYP1A2CYP2C9ALOX15 | |
| SCHEMBL449400 | 0.73 | ELANE (0.39) | CYP3A4CYP2D6LMNA | |
| SCHEMBL8381354 | 0.73 | KCNQ2 (0.58) | KCNQ2CYP3A4CYP1A2CYP2C9ALOX15 | |
| Hydrochloric Acid SCHEMBL27203219 | 0.72 | KCNQ2 (0.97) | KCNQ2CYP3A4CYP1A2CYP2C9ALOX15 | |
| Hydrochloric Acid SCHEMBL9265822 | 0.71 | KCNQ2 (0.77) | KCNQ2CYP3A4CYP1A2CYP2C9ALOX15 | |
| SCHEMBL2761225 | 0.70 | KCNQ2 (1.00) | KCNQ2CYP3A4CYP1A2CYP2C9ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0311010-B1 | Alpha,Alpha-disubstituted aromatics and heteroaromatics as cognition enhancers | DU PONT MERCK PHARMA (US) | 1994-02-02 | — | — | EP | claimed |
| EP-0311010-A2 | Alpha,Alpha-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1989-04-12 | — | — | EP | claimed |
| US-5434264-A | α,α-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| US-5300642-A | α, α-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0311010-B1 | Alpha,Alpha-disubstituted aromatics and heteroaromatics as cognition enhancers | DU PONT MERCK PHARMA (US) | 1994-02-02 | — | — | EP | disclosed |
| EP-0532054-A1 | Process for preparing alpha,alpha-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-03-17 | — | — | EP | disclosed |
| US-5173489-A | α,α-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DUPONT MERCK PHARMACEUTICAL CO. (US) | 1992-12-22 | — | — | US | disclosed |
| US-5171745-A | Administering to the mammal a combination of at least one strotonin receptor with neurotransmitter enhancer; useful for parkinson's/alzheimer's diseases, mental retardation, myasthenia gravis and senile-dementia | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-12-15 | — | — | US | disclosed |
| EP-0311010-A2 | Alpha,Alpha-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1989-04-12 | — | — | EP | disclosed |